MCID: BLD131
MIFTS: 51

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Urothelial Carcinoma

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 14
Transitional Cell Carcinoma of Bladder 12 69
Transitional Cell Carcinoma of the Bladder 29
Urinary Bladder Urothelial Carcinoma 12
Bladder Transitional Cell Carcinoma 12
Carcinoma Transitional Cell Bladder 52
Urothelial Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4006
NCIt 47 C39851
SNOMED-CT 64 255109008 393562002
UMLS 69 C0279680

Summaries for Bladder Urothelial Carcinoma

Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of bladder, is related to lipid-cell variant infiltrating bladder urothelial carcinoma and non-papillary transitional cell carcinoma of the bladder. An important gene associated with Bladder Urothelial Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MicroRNAs in cancer. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and prostate, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
id Related Disease Score Top Affiliating Genes
1 lipid-cell variant infiltrating bladder urothelial carcinoma 33.8 KRT7 TP53
2 non-papillary transitional cell carcinoma of the bladder 12.3
3 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.1
4 clear cell variant infiltrating bladder urothelial carcinoma 12.0
5 non-invasive bladder urothelial carcinoma 12.0
6 micropapillary variant infiltrating bladder urothelial carcinoma 12.0
7 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.0
8 nested variant infiltrating bladder urothelial carcinoma 12.0
9 microcystic variant infiltrating bladder urothelial carcinoma 12.0
10 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.0
11 invasive bladder transitional cell carcinoma 11.0
12 renal pelvis urothelial papilloma 10.8 CDH1 TP53
13 angioma serpiginosum 10.8 CDH1 KRT20
14 follicular basal cell carcinoma 10.8 CDH1 KRT20
15 ampulla of vater squamous cell carcinoma 10.8 CDH1 KRT20
16 small intestine leiomyoma 10.8 KRT20 TP53
17 rhizomelic chondrodysplasia punctata, type 3 10.8 CASP3 TP53
18 plexosarcoma 10.7 CCND1 FGFR3
19 gorlin bushkell jensen syndrome 10.7 CDH1 KRT20
20 animal phobia 10.7 CCND1 TP53
21 childhood teratoma of the ovary 10.7 CDH1 KRT20
22 rhinosporidiosis 10.7 KRT20 UPK3A
23 rete testis adenoma 10.7 TP53 UPK3A
24 ductal carcinoma in situ 10.7 CCND1 CDH1 TP53
25 maxillary neoplasm 10.7 CCND1 CDH1 TP53
26 hodgkin's lymphoma, mixed cellularity 10.6 CCND1 CDH1 TP53
27 estrogen-receptor negative breast cancer 10.6 CCND1 CDH1 TP53
28 oral antidiabetic drugs toxicity or dose selection 10.6 CCND1 FHIT TP53
29 breast mucinous cystadenocarcinoma 10.6 KRT20 UPK3A
30 paroxysmal nocturnal hemoglobinuria 10.6 CCND1 CDH1 TP53
31 tracheal disease 10.6 CASP3 CDH1 TP53
32 intrahepatic bile duct adenoma 10.6 FGFR3 KRT20 TP53
33 extrahepatic bile duct adenoma 10.6 FGFR3 KRT20 TP53
34 breast granular cell tumor 10.6 CCND1 CDH1 TP53
35 breast pericanalicular fibroadenoma 10.6 KRT20 TP53
36 bone giant cell tumor 10.6 KRT20 KRT7
37 rectum adenoma 10.5 KRT20 KRT7
38 chest wall lymphoma 10.5 CCND1 TP53
39 arrhythmogenic right ventricular cardiomyopathy 10.5 CCND1 CDH1 TP53
40 periosteal osteogenic sarcoma 10.5 KRT20 KRT7
41 pulmonary embolism and infarction 10.5 GATA3 TP53
42 sensory system cancer 10.5 KRT20 KRT7
43 mediastinum seminoma 10.5 FGFR3 TP53 UPK3A
44 steroid-induced glaucoma - borderline 10.5 KRT20 KRT7
45 ludwig's angina 10.5 KRT20 KRT7
46 lung occult small cell carcinoma 10.5 KRT20 KRT7
47 fibroepithelial polyp of urethra 10.5 KRT20 KRT7
48 kidney osteogenic sarcoma 10.5 KRT7 UPK3A
49 monoclonal paraproteinemia 10.5 CASP3 CDH1 KRT20
50 clear cell squamous cell skin carcinoma 10.5 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 RB1 TGFBR3 TP53 AGGF1 CASP3 CCND1
2 homeostasis/metabolism MP:0005376 10.06 CASP3 CCND1 CDH1 FGFR3 FHIT GATA3
3 digestive/alimentary MP:0005381 9.97 CASP3 CCND1 CDH1 FGFR3 FHIT GATA3
4 craniofacial MP:0005382 9.88 CASP3 CCND1 FGFR3 GATA3 RB1 TP53
5 integument MP:0010771 9.86 CASP3 CCND1 CDH1 FGFR3 FHIT GATA3
6 neoplasm MP:0002006 9.7 AGGF1 CCND1 CDH1 FGFR3 FHIT RB1
7 renal/urinary system MP:0005367 9.5 CASP3 FGFR3 GATA3 KRT7 RB1 TP53
8 reproductive system MP:0005389 9.23 RB1 TGFBR3 TP53 CASP3 CCND1 CDH1

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
4
Selenium Approved, Vet_approved Phase 3 7782-49-2
5
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
12
Aminolevulinic acid Approved Phase 3 106-60-5 137
13
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
14
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
15
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
16
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
17
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 453 6251
18
Ramucirumab Approved, Investigational Phase 3,Phase 2 947687-13-0
19
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
20
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
22
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
23
Ethanol Approved Phase 3 64-17-5 702
24
Cephalexin Approved, Vet_approved Phase 3 15686-71-2 27447
25
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
26 Tocopherol Approved, Nutraceutical Phase 3
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
29
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 59-67-6 938
30
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2,Phase 1 98-92-0 936
31
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
32
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262 389
33
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
34
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 231277-92-2, 388082-78-8 208908 9941095
35
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1
36
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
37
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
38
Levulinic acid Experimental Phase 3 123-76-2 11579
39
Fenretinide Investigational Phase 3 65646-68-6
40
Apaziquone Investigational Phase 3 114560-48-4 5813717
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
44 Antiviral Agents Phase 3,Phase 2,Phase 1
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
46 Liposomal amphotericin B Phase 2, Phase 3
47 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
48 Antioxidants Phase 3
49 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
50 Protective Agents Phase 3,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 327)

id Name Status NCT ID Phase Drugs
1 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
2 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
3 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Unknown status NCT01668459 Phase 2, Phase 3 Cabazitaxel
4 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
5 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
6 Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer Unknown status NCT00553566 Phase 3
7 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
8 Quality of Life in Patients With Bladder Cancer Unknown status NCT00553215 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
10 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
11 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
12 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
13 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
14 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
15 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
16 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
17 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
18 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
19 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
20 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
21 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
22 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
23 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
24 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
25 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
26 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3 Cisplatin
27 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
28 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
29 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
30 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
31 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
32 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
33 Bladder Cancer Adjuvant Radiotherapy Trial Recruiting NCT02951325 Phase 3
34 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
35 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
36 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Recruiting NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine
37 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
38 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3 Chemotherapy
39 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
40 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Recruiting NCT02807636 Phase 3 Atezolizumab;Carboplatin;Gemcitabine;Cisplatin
41 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
42 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
43 A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT Active, not recruiting NCT02563561 Phase 3 Apaziquone
44 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
45 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
46 BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Terminated NCT00352079 Phase 3 gefitinib
47 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
48 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
49 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
50 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3 mitomycin C

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

id Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29

Anatomical Context for Bladder Urothelial Carcinoma

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

39
Kidney, Lymph Node, Prostate, Lung, Testes, Bone, Endothelial

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 83)
id Title Authors Year
1
Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. ( 28356754 )
2017
2
Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma. ( 28488128 )
2017
3
Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. ( 28347658 )
2017
4
Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. ( 28396613 )
2017
5
Clinicopathological implications to micropapillary bladder urothelial carcinoma of the presence of sialyl Lewis X-decorated mucin 1 in stroma-facing membranes. ( 28666720 )
2017
6
Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-I_B/MMP-7 signaling pathway. ( 28333147 )
2017
7
Bladder urothelial carcinoma extending to rectal mucosa and presenting with rectal bleeding. ( 28690772 )
2017
8
Expression of AR, 5I+R1 and 5I+R2 in bladder urothelial carcinoma and relationship to clinicopathological factors. ( 28947209 )
2017
9
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. ( 28291636 )
2017
10
Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. ( 28789622 )
2017
11
High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma. ( 27959455 )
2017
12
A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. ( 28060759 )
2017
13
Contrast-Enhanced Ultrasound Differentiation Between Low- and High- Grade Bladder Urothelial Carcinoma and Correlation With Tumor Microvessel Density. ( 28556470 )
2017
14
The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway. ( 28548944 )
2017
15
Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. ( 28600503 )
2017
16
Vaginal metastasis of bladder urothelial carcinoma: Description of a case and revision of literature. ( 28679193 )
2017
17
Independent prognostic miRNAs for bladder urothelial carcinoma. ( 28928837 )
2017
18
Mex3a expression and survival analysis of bladder urothelial carcinoma. ( 28903380 )
2017
19
Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway. ( 27440446 )
2016
20
Female, Black, and Unmarried Patients Are More Likely to Present With Metastatic Bladder Urothelial Carcinoma. ( 27212042 )
2016
21
A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. ( 26812572 )
2016
22
The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. ( 27341738 )
2016
23
Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. ( 27181205 )
2016
24
Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma. ( 26852969 )
2016
25
Retrospective study of various conservative treatment options with bacille Calmette-GuAcrin in bladder urothelial carcinoma T1G3: Maintenance therapy. ( 26922518 )
2016
26
Evaluation of the role of immunohistochemical expression of EGFR (ERB B1) and HER4 (ERB B4) in urinary bladder urothelial carcinoma. ( 27772841 )
2016
27
Clarification of the molecular pathway of Taiwan local pomegranate fruit juice underlying the inhibition of urinary bladder urothelial carcinoma cell by proteomics strategy. ( 26955879 )
2016
28
Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma. ( 27599849 )
2016
29
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. ( 26869805 )
2016
30
Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. ( 27505309 )
2016
31
Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance. ( 27752905 )
2016
32
Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience. ( 27563483 )
2016
33
Differential effects of adipose tissue stromal cells on the apoptosis, growth and invasion of bladder urothelial carcinoma between the superficial and invasive types. ( 27020040 )
2016
34
The expression of AEG-1 and Cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance. ( 26885058 )
2015
35
Decrement of miR-199a-5p contributes to the tumorigenesis of bladder urothelial carcinoma by regulating MLK3/NF-I_B pathway. ( 26885275 )
2015
36
Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells. ( 26339359 )
2015
37
E-cadherinA^CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas. ( 25826491 )
2015
38
Significance of suppressor of cytokine signaling-3 expression in bladder urothelial carcinoma in relation to proinflammatory cytokines and tumor histopathological grading. ( 25640370 )
2015
39
Urinary bladder urothelial carcinoma with concurrent plasmacytoid and micropapillary differentiations: A report of two cases with an emphasis on serum carbohydrate antigen 19-9. ( 26044127 )
2015
40
T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. ( 26265374 )
2015
41
The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. ( 25940704 )
2015
42
Suppression of Cellular Proliferation and Invasion by HMGB1 Knockdown in Bladder Urothelial Carcinoma Cells. ( 26629935 )
2014
43
Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. ( 25368291 )
2014
44
A case of urinary bladder urothelial carcinoma with squamous, glandular, and plasmacytoid differentiation. ( 24987357 )
2014
45
Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. ( 24462738 )
2014
46
I+4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. ( 24388773 )
2014
47
Prognostic significance of Nestin expression in pT1 high- grade bladder urothelial carcinoma patients treated with intravesical BCG. ( 25605182 )
2014
48
Overexpression and clinicopathological contribution of DcR3 in bladder urothelial carcinoma tissues. ( 25422191 )
2014
49
Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2. ( 23276457 )
2013
50
Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. ( 23696935 )
2013

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 90)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
4 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
14 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
17 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
18 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
20 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
21 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
24 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
25 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
26 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
27 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
28 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
29 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
30 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
31 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
32 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
33 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
34 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
35 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
36 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
37 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
38 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
39 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
40 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
41 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
42 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
43 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
44 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
45 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
46 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic/Likely pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
47 MAP2K1 NM_002755.3(MAP2K1): c.371C> T (p.Pro124Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397516792 GRCh37 Chromosome 15, 66729163: 66729163
48 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
50 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275

Cosmic variations for Bladder Urothelial Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 18

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1 12.54 CASP3 CCND1 FGFR3 RB1 TP53
2 12.37 CASP3 CCND1 FGFR3 TP53
3 12.33 CASP3 CCND1 CDH1 FGFR3 RB1 TP53
4
Show member pathways
12.29 CASP3 FGFR3 TGFBR3 TP53
5 12.28 CCND1 CDH1 RB1 TP53
6
Show member pathways
12.22 CASP3 CCND1 RB1 TP53
7
Show member pathways
12.22 CASP3 CCND1 CDH1 FGFR3 FHIT RB1
8 12.21 CCND1 CDH1 RB1 TP53
9 12.14 CASP3 CCND1 RB1 TP53
10
Show member pathways
12.1 CASP3 CCND1 RB1 TP53
11 11.98 CASP3 CCND1 CDH1 TP53
12
Show member pathways
11.98 CASP3 CCND1 FGFR3 RB1 TP53
13 11.84 CCND1 GATA3 TP53
14 11.82 CCND1 RB1 TP53
15 11.78 CASP3 CCND1 RB1 TP53
16 11.74 CASP3 CCND1 CDH1 RB1 TP53
17 11.7 CCND1 RB1 TP53
18 11.42 CASP3 CCND1 TP53
19 11.38 CASP3 CCND1 TP53
20 11.36 CCND1 RB1 TP53
21 11.28 CASP3 CCND1 FHIT RB1 TP53
22 11.27 CASP3 RB1 TP53
23 10.96 CCND1 CDH1 FGFR3 RB1 TP53 UPK3A
24 10.94 GATA3 TGFBR3

GO Terms for Bladder Urothelial Carcinoma

Cellular components related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 AGGF1 CASP3 CCND1 CDH1 EMP2 FGFR3

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.73 CASP3 CCND1 CDH1 GATA3
2 response to organic substance GO:0010033 9.54 CASP3 CCND1 CDH1
3 positive regulation of transcription regulatory region DNA binding GO:2000679 9.4 GATA3 RB1
4 negative regulation of cell cycle GO:0045786 9.33 CASP3 GATA3 RB1
5 mitotic G1 DNA damage checkpoint GO:0031571 9.32 CCND1 TP53
6 glial cell apoptotic process GO:0034349 9.26 CASP3 RB1
7 apoptotic process GO:0006915 9.17 CASP3 FGFR3 FHIT KRT20 RB1 TNFRSF6B
8 response to X-ray GO:0010165 9.13 CASP3 CCND1 TP53

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 AGGF1 CASP3 CCND1 CDH1 EMP2 FGFR3
2 transcription factor binding GO:0008134 9.46 CCND1 GATA3 RB1 TP53
3 kinase binding GO:0019900 9.13 EMP2 LDHB RB1

Sources for Bladder Urothelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....